Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
RESEARCH TOOLSreports
Holding ALXO?
Track your performance easily
ALXO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $17.83
Previous Close$2.32
Volume860.72K
Average Volume (3M)1.41M
Market Cap
$121.15M
Enterprise Value-$25.81M
Total Cash (Recent Filing)$156.72M
Total Debt (Recent Filing)$9.77M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Nov 13, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding52,671,790
10 Day Avg. Volume787,794
30 Day Avg. Volume1,407,797
Standard Deviation0.30
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$8.80Price Target Upside279.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
ALX Oncology Holdings News
PremiumCompany Announcements
ALX Oncology Enhances Board with Expert Appointment, Meets Nasdaq Standards
Bulls Say, Bears Say
Bulls Say
Clinical Development StrategyThe Phase 2 data not only validated the mechanism of action of Evo, but also de-risked its development in other tumor indications, including HNSCC, breast cancer, B-cell NHL, and multiple myeloma.
Clinical Trial ResultsThe topline results showed a confirmed objective response rate (ORR) and median duration of response (DOR) of 40.3% and 15.7 months in the evorpacept + TRP arm vs. 26.6% and 7.6 months in the TRP arm.
Financial PerformanceALX Oncology reported cash and cash equivalents of approximately $186M at the end of 2Q24, which is believed to be sufficient to fund operations.
Bears Say
Adverse Events25% of patients experienced evo-related Grade 3-4 AEs, including Grade 4 neutrophil count decrease, thrombocytopenia, and anemia.
Clinical Data ConcernsThe progression free survival (PFS) and overall survival (OS) data are currently immature, and are both important endpoints needed to form a clearer conclusion.
Stock PerformanceThe stock is down meaningfully after hours.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $2.25 and its highest was $17.82 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
Currently, no data Available
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Nov 13, 2024 which is in 74 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Aug 08, 2024. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.748 by -$0.012.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -$0.78.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 52,671,790 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.748. Following the earnings report the stock price went down -0.76%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Among the largest hedge funds holding ALX Oncology Holdings’s share is Graham Capital Management, L.P.. It holds ALX Oncology Holdings’s shares valued at 144K.
---
ALX Oncology Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.80 (279.31% Upside)
$8.80 (279.31% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 78%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 21.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $737.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.66%
12-Months-Change
Fundamentals
Return on Equity
-92.17%
Trailing 12-Months
Asset Growth
-12.73%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
---
ALXO Stock 12 Month Forecast
Average Price Target
$8.80
▲(279.31% Upside)
Technical Analysis
RAPT Therapeutics
―
Corvus Pharmaceuticals
―
Aileron Therapeutics
―
Cara Therapeutics
―
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-25.20%
reiterated a buy rating 19 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -25.20% per trade.
---